TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01451515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given orally (PO).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given intravenously (IV).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Given IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-asparaginase
Description: Given intramuscularly (IM) or IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erwinia asparaginase
Description: Given IM or IV if allergy occurs with the first or second PEG-asparaginase dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV or IT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thioguanine
Description: Given PO.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Given IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV, IM or IT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given PO.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO or IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Given IT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV.
Study: NCT01646710

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pretesting food based recommendations
Study: NCT01563601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obatoclax Mesylate, Carboplatine and Etoposide
Description: Obatoclax Mesylate:~30 mg fixed dose;administered IV on days 1-3 every 21 days for 6 cycles. Maintenance therapy (optional and only if documented CR or PR) with obatoclax mesylate is administered at the same IV dose on days 1-3 every 21 days until disease progression or death.~Carboplatin:~Dose targeted at AUC of 5; administered IV on Day 1 only every 21 days for 6 cycles~Etoposide:~100mg/m2 administered IV on Days 1-3 every 21days for 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin and Etoposide
Description: Carboplatin:~Dose targeted at AUC of 5 administered IV on Day 1 only every 21 days for 6 cycles.~Etoposide:~100mg/m2 administered IV on Days 1-3 every 21 days for 6 cycles
Study: NCT00775021

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A
Description: Contact Lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A
Description: Contact Lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nelfilcon A
Description: Contact Lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nelfilcon A
Description: Contact Lens
Study: NCT00685282

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive Behavioral Therapy
Description: The intervention (CBT) will focus on teaching specific skills which are adapted for women undergoing fertility related problems. Through the sessions the participants will learn relaxation techniques such as breathing, progressive relaxation, and guided imagery. Furthermore, suggestions for making healthier choices for coping and for releasing tension will be reviewed and discussed, with an emphasis on making healthy lifestyle changes with balance and perspective rather than in a punishing or depriving way. Each session will consist of: 20 minutes of stress-reduction behavioral relaxation, 40 minutes of cognitive restructuring and 30 minutes personal tailoring of the behavioral homework between each session.
Study: NCT03464838

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Description: Transcranial direct current stimulation (tDCS) is a form of noninvasive brain stimulation that applies a very low electrical current to the scalp. tDCS will be applied with intensity of 1.8 milliamps in real stimulation condition and 0 milliamps in sham condition, during 20 minutes, using a high density (HD) tDCS montage over the Prefrontal Cortex (PFC). Electroencephalography (EEG) resting state activity will be measured before and after tDCS.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS)
Description: Transcranial direct current stimulation (tDCS) is a form of noninvasive brain stimulation that applies a very low electrical current to the scalp. tDCS will be applied with intensity of 1.8 milliamps in real stimulation condition and 0 milliamps in sham condition, during 20 minutes, using a high density (HD) tDCS montage over the Prefrontal Cortex (PFC). Electroencephalography (EEG) resting state activity will be measured before and after tDCS.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Description: Cognitive Behavioural Therapy (CBT) is the current treatment available for disordered gamblers at the UK National Problem Gambling Clinic. During the therapy sessions patients acquire learning strategies, cognitive and motivational elements, and develop personal skills to help them improve the understanding of their problems.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Cognitive Behavioural Therapy (CBT)
Description: Cognitive Behavioural Therapy (CBT) is the current treatment available for disordered gamblers at the UK National Problem Gambling Clinic. During the therapy sessions patients acquire learning strategies, cognitive and motivational elements, and develop personal skills to help them improve the understanding of their problems.
Study: NCT00818272

Intervention type: BIOLOGICAL
Intervention: Remicade (infliximab)
Description: Participants with confirmed diagnosis of severe active Crohn's disease (CD) and participants suffering from fistulae who do not respond sufficiently to a complete and adequate therapy with a conventional treatment received infliximab administration as intravenous (IV) infusion over a period of two hours. Dosage and infusion intervals were employed in accordance to the Summary of Product Characteristics (SmPC): 5 mg/kg body weight at week 0 of infliximab therapy with additional infusions of 5 mg/kg at week 2 and week 6 after the initial dose, followed by infusions every 8 weeks (maintenance) or if signs and symptoms of the disease recur (readministration).
Study: NCT01175720

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periodontal surgery to gingival recessions
Description: Test and control technique to treat gingival recessions.
Study: NCT06417515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xiao-Yao-San
Description: Patients who received Xiao-Yao-San 9 g/day (Kaiser Pharmaceutical Co. Ltd.) were selected for the Xiao-Yao-San group by traditional Chinese doctor with 8 years of experience.

Intervention type: OTHER
Group type: OTHER
Intervention: Weight loss class(WLC) group
Description: Participants who attended the WLCs in our hospital and were willing to participate in our study were included in the WLC group (control group). Our WLCs consisted of 8 sessions of 2-hour dietary advice/exercise guidance and 1 session of weight-loss consultation in 3 months. The participants assessed their weights at the beginning, at 1.5 months, and after every class. They underwent pre-PSG tests in the beginning and post-PSG tests after 3 months of lectures.
Study: NCT00442598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glufosfamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glufosfamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glufosfamide
Study: NCT00359892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obatoclax mesylate (GX15-070MS)
Description: 60 mg q2wks
Study: NCT01962220

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Study Intervention for Retention (APFU)
Description: Each newly identified HIV-infected pregnant woman randomized to the experimental arm will be assigned an outreach worker/counselor (Mama Mshauri).~Mama Mshauri tasks will include:~* Immediately engaging the newly identified pregnant woman, providing individualized adherence and disclosure support, management of ART side effects, and helping the client navigate the health system.~* Providing tailored individualized health education during home visits.~Additional intervention components include:~* Appointments and Reminders: SMS or telephone reminders 1 week and 3 days before appointments. Reinforcement of importance of follow-up during home visits and every contact.~* Patient Tracking and Defaulter Tracing: Monthly visits and immediate calls/home visit if she misses an appointment.
Study: NCT04076826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine infusion will be commenced in accordance with the hospital's local sedation protocol, without a loading dose, at a rate of 0.1 - 1.4 mcg/kg/hour to maintain sedation as per Richmond Agitation-Sedation Scale (RASS) sedation range specified by the treating clinician. Infusion will be continued until sedation is no longer clinically indicated up to a maximum of 7 days after enrolment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol or Midazolam
Description: Propofol and/or Midazolam will be used according to Hospital guidelines to maintain sedation as per Richmond Agitation-Sedation Scale (RASS) sedation range specified by the treating clinician.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: In all participants, we will collect blood samples for measurement of neuronal and systemic biomarkers of inflammation at randomization (baseline), at day 1, day 2 and day 3 after randomization.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Blood sampling
Description: In all participants, we will collect blood samples for measurement of neuronal and systemic biomarkers of inflammation at randomization (baseline), at day 1, day 2 and day 3 after randomization.
Study: NCT01974323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapsone Gel
Description: Dapsone gel applied topically to the face and to affected areas of the trunk once daily for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dapsone Gel Vehicle
Description: Dapsone gel vehicle applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
Study: NCT01926587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral rigosertib
Description: Oral rigosertib will be administered twice a day in fasting conditions for weeks 1, 2, and 3 of a 4-week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Starting on Day 1 of second week (Day 8) of the cycle, azacitidine will be administered by subcutaneous injection or intravenous infusion at the labeled daily dose of 75 mg/m2, for 7 days.
Study: NCT00466505

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: 400 mg/m2 iv week 1, then 250 mg/m2 weekly thereafter, starting on day 1 and continuing until progressive disease, excessive toxicity or removal from study for other reasons listed in the protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: 200 mg po BID starting on day 1 and continuing until progressive disease, excessive toxicity or removal from study for other reasons listed in the protocol.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: proteomic profiling
Description: Serum samples obtained as above will be analyzed by proteomic analysis in order to determine biomarkers of treatment response and toxicity prediction. We will use LC-MS-MS or MALDITOF mass spectrometry.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: phospho-EGFR levels using western blots of tissue extracts and immunohistochemistry on frozen and (if no other option available, paraffinembedded tissue sections).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Serum samples obtained as above will be analyzed by proteomic analysis in order to determine biomarkers of treatment response and toxicity prediction.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mass spectrometry
Description: We will use LC-MS-MS or MALDITOF mass spectrometry. Before any tissues are received, the drug of interest is evaluated via MALDI mass spectrometry on a MDS/Sciex QStar QqTOF mass spectrometer.
Study: NCT04240756

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Parent Training
Description: Parents will receive 10 sessions of behavioral parent training with components specifically targeted toward parents with ADHD. Treatment will be delivered via telehealth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended release mixed amphetamine salts (MAS)
Description: The MAS protocol will include a 2-4 -week open-label titration beginning at 20 mg and dose level will be increased weekly at telehealth visits with the psychopharmacologist until an optimal response or maximum dose of 60 mg.
Study: NCT01285193

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breath control
Description: A music CD with sound cues is used to guide the subject to breathe in a regular and slower rate. This is practiced for at least 15 minutes a day over 2 months.
Study: NCT02336581

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Description: individual + group + follow-up phone contacts

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Treatment as Usual (eTAU)
Description: individual + group + follow-up phone contacts
Study: NCT03458429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GMFFP
Description: Granulocyte-Colony Stimulating Factor (G-CSF) Mobilized Fresh Frozen Plasma
Study: NCT01750593

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation of the thyroid nodule
Description: Under USG control, the nodule will be ablated by radiofrequency with a needle that has an active tip of 1 cm.
Study: NCT01346761

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Genetic Counseling
Description: Participants will complete a pre-test session and a test results disclosure session (if tested) with a licensed, board-certified genetic counselor over the telephone. Counseling sessions will be audiotaped for quality control of intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In-Person Genetic Counseling
Description: Participants will complete a pre-test session and a test results disclosure session (if tested) with a licensed, board-certified genetic counselor in person. Counseling sessions will be audiotaped for quality control of intervention.
Study: NCT03442023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate at 2%
Description: Mouth Rinse with Chlorhexidine gluconate at 2% every 12 hours, one week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine gluconate at 0.12%
Description: Mouth Rinse with Chlorhexidine gluconate at 0.12% every 12 hours, one week.
Study: NCT03786016

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 8-Days in an Isolation, Confinement Unit
Description: Subjects will spend 8 days/7 nights continuously in an isolated and confined unit with up to 3 other subjects. Subjects will participate in daily, timed activities such as space-relevant computer simulations, team tasks, and cognitive performance testing. Subjects will also experience altered environmental conditions (such as changes in lighting, sound and ambient temperature) while in the isolation unit. Subjects will receive orders from mission control who will monitor activity in the isolation unit and direct subjects throughout the 8-day study.
Study: NCT01050075

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture therapy
Description: acupuncture therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture therapy
Description: acupuncture therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: management of therapy complications
Description: To be determined by the treating physician

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: management of therapy complications
Description: To be determined by the treating physician
Study: NCT02774408

Intervention type: DEVICE
Group type: OTHER
Intervention: Saturation sensitive backup ventilation

Intervention type: DEVICE
Group type: OTHER
Intervention: Saturation sensitive backup ventilation
Study: NCT02548559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Full-Spectrum Cannabidiol
Description: Full-Spectrum Cannabidiol; total daily dose of 30 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single-Compound Cannabidiol
Description: Single-Compound Cannabidiol; total daily dose of 30 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution.
Study: NCT01603420

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Luteinizing hormone-releasing hormone (LHRH)
Description: Androgen suppression therapy using luteinizing hormone-releasing hormone (LHRH) agonists such as leuprolide, goserelin, buserelin, triptorelin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luteinizing hormone-releasing hormone (LHRH)
Description: Androgen suppression therapy using luteinizing hormone-releasing hormone (LHRH) agonists such as leuprolide, goserelin, buserelin, triptorelin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 20mg/m2 IV every 7 days x 8 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conformal Radiation Therapy (RT)
Description: 1.8 Gy(RBE) (or Gy for IMRT) per fraction,five fractions per week for a total dose of 79.2 Gy (RBE) (or Gy).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conformal Radiation Therapy (RT)
Description: 1.8 Gy(RBE) (or Gy for IMRT) per fraction,five fractions per week for a total dose of 79.2 Gy (RBE) (or Gy).
Study: NCT02822170

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IV amino acids and in-bed cycle ergometry
Description: IV amino acids and in-bed cycle ergometry
Study: NCT03406793

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standard MNP
Description: Standard MNP, 15 micronutrients (Vitamin A 400 µg, vitamin D 5 µg, vitamin E 5 mg, vitamin C 30 mg, thiamine 0.5 mg, riboflavin 0.5 mg, niacin 6 mg, pyridoxine 0.5 mg, vitamin B12 0.9 mg, folate 150 µg, iron 10 mg, zinc 4.1 mg, copper 0.56 mg, selenium 17.0 µg and iodine 90 µg). Daily supplementation for 24 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High zinc, low iron MNP
Description: Same as group 1, except with 10 mg zinc instead of 4.1 mg and 6 mg iron instead of 10 mg. Daily supplementation for 24 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High zinc, low/no iron on alternating days
Description: Same as study group 1, except with 10 mg zinc instead of 4.1 mg, and 6 mg iron and no iron on alternating days instead of 10 mg. Daily supplementation for 24 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dispersible zinc supplement
Description: 10 mg zinc in a dispersible tablet. Daily supplementation for 24 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intermittent zinc supplement
Description: 10 mg zinc in a dispersible tablet. Daily supplementation for 14 days at baseline and 3 months, placebo tablet on all other days.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo powder
Description: Daily provision of a placebo powder for 24 weeks.
Study: NCT02100540

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: I placebo capsule
Description: I placebo capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: II RDC 0.3mg capsule
Description: II RDC 0.3mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: III RDC 0.6mg capsule
Description: III RDC 0.6mg capsule
Study: NCT03959774

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IPC NET
Description: a digital pack with connected bracelet and connected balance will be given to the patient. IPC NET and Nokia Health applications will be downloaded. Pairing between connected objects and the smartphone will be done during the inclusion visit
Study: NCT03604263

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ArcticLine Cardiac Cryoablation Catheter
Description: Cryoablation
Study: NCT02550132

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal manipulation
Description: Participants will lie down during the 45-minute experimental session. Vertebral displacements (cm) and muscle response amplitude (RMS value) will be recorded through kinematic markers (on T6, T7 and T8 spinous processes) and surface electromyography electrodes (on the left and right erector spinae at T6 and T8 vertebra level). Each SMT (4 per participant) will be delivered at T7 transverse processes by an apparatus. Responses during the thrust phase (duration equal to twice the time to peak force) and after the thrust (1,5s duration) will be compared between SMTs.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apparatus used to deliver spinal manipulations
Description: An apparatus using a servo-controlled linear actuator motor (Linear Motor Series P01-48x360, LinMot Inc., Switzerland) will be used to deliver spinal manipulations.
Study: NCT00504257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin
Description: Day 1, every 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Day 1, 8, every 21 day cycle
Study: NCT04007614

Intervention type: OTHER
Intervention: Questionnaire
Description: Fardellone questionnaire (evaluation of calcium intake) Tolerance of treatment
Study: NCT03585114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [F-18] DCFPyL
Description: \[18F\]DCFPyL will be used for study imaging. It will be administered intravenously on the day of imaging. Subjects will receive a bolus injection of 9mCi (331 MBq) of \[18F\]DCFPyL through a peripheral IV catheter. 60 to 120 minutes after injection, a whole body (toes to vertex) lowdose CT will be obtained (120 kVp, 80 mA maximum).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET/CT imaging
Description: As per standard of care, acquisition will be performed on PET/CT scanner (Siemens, Germany) operating in 3D emission mode with CT-derived attenuation correction.